Heart BMJ

MARCH 26, 2025

Background Heart failure with preserved ejection fraction is a recognised outcome in patients with myocardial infarction, although heart failure with reduced ejection fraction is more common. fold higher risk of heart failure with preserved ejection fraction (95% CI 1.30

Aortic valve 52

Aortic valve Myocardial Infarction Preserved Ejection Fraction Heart Failure 52

Heart BMJ

MARCH 26, 2025

Heart failure (HF) is one of the significant complications in patients with myocardial infarction (MI), leading to increased risk for cardiovascular morbidity and mortality. 2 However, mortality rate is greater in HF cases developing >3 days following MI compared with less than or equal to 3 days after MI.

Myocardial Infarction 52

Myocardial Infarction Preserved Ejection Fraction Heart Failure Aortic valve 52

European Journal of Heart Failure

DECEMBER 28, 2023

Abstract Aims Preventive strategies for heart failure (HF) with preserved ejection fraction (HFpEF) include pharmacotherapies and lifestyle modifications. All had no evidence of HF or myocardial infarction prior to completion of the ETT. years and 43,179 women; mean age 55.0±8.9 years) year apart.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Myocardial Infarction Article 40

Circulation: Heart Failure

NOVEMBER 25, 2024

Circulation: Heart Failure, Volume 17, Issue 12 , Page e011629, December 1, 2024. Spironolactone, a steroidal mineralocorticoid receptor antagonist (MRA), has been used to treat patients with heart failure (HF) for more than half a century. The use of MRAs has been limited due to excessive concern about hyperkalemia.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Myocardial Infarction Kidney Disease 40

Frontiers in Cardiovascular Medicine

OCTOBER 10, 2024

ObjectiveTo investigate the therapeutic effect of Vericiguat combined with “new quadruple” drugs on patients with heart failure (HF).MethodsFrom Patients diagnosed with preserved ejection fraction (HFpEF) were treated with Vericiguat combined with “ARNI, BB, SGLT2i” therapy.

Heart Failure 52

Heart Failure Preserved Ejection Fraction Cardiac Function Quality of Life 52

Circulation

NOVEMBER 11, 2024

All-cause hospitalization (HR: 2.31, 95%CI: 2.04 – 2.62, p<0.001), heart failure hospitalization (HR: 2.22, 95%CI: 1.92 – 2.55, p<0.001), acute myocardial infarction (HR: 2.06, 95%CI: 1.79 – 2.35, p<0.001), unstable angina (HR: 2.28, 95%CI: 1.72-3.04,

Heart Failure 40

Heart Failure Preserved Ejection Fraction Bicuspid/Mitral Outcomes 40

DAIC

FEBRUARY 29, 2024

ET Main Tent (Hall B1) - A Double-blind, Randomized Placebo Procedure-controlled Trial of an Interatrial Shunt in Patients with HFrEF and HFpEF: Principal Results From the RELIEVE-HF Trial - Empagliflozin After Acute Myocardial Infarction: Results of the EMPACT-MI Trial - CSL112 (Apolipoprotein A-I) Infusions and Cardiovascular Outcomes in Patients (..)

Aortic valve 103

Aortic valve Myocardial Infarction Aortic Blood Pressure 103